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Scomplications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
TCT-515
THEMULTILAYER FLOWMODULATOR STENT FOR THE TREATMENT
OF THORACO ABDOMINAL AND ABDOMINAL AORTIC ANEURYSMS.
MAROCCAN EXPERIENCE
Michel C. Henry1, Amira Benjelloun2, Isabelle P. Henry3
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Background: Thoraco Abdominal Aortic Aneurysms (TAAA) and Abdominal Aortic
Aneurysms (AAA) are traditionally treated surgically, but more and more by inter-
ventional procedures (endografts, fenestrated, branched grafts, chimney techniques).
We used a new concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
Methods: This selfexpandable M.F.M is a 3 D braided tube made of several inter-
connected layers without any covering. We will explain and demonstrate the key
principles of the stent leading to thrombosis, shrinkage of the A, eliminating the risk of
rupture. Moreover, this M.F.M preserves the collateral branches allowing the possi-
bility to cover any artery without compromising the ﬂow (renal, digestive arteries,
supra aortic vessels.).
Results: 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated with MFM
in very high risk patients. 53 MFM implanted (1 to 5 per pt). o Technical success:
100% o At 30 days: no neurological complication, branch patency 100%, no death o
During the follow up we had 3 deaths not device related. CT scan control performed
at 1, 3, 6, 12, 18 months with calculation of A. Diameters and Volumes. o All
collateral branches remain patent and we observed a progressive thrombosis
and shrinkage of the aneurysmal sac depending on the size of the collaterals.
Some patients developed a thrombus after 1 month, some after 6 months and some-
even after 18 months. A signiﬁcant mean diameter reduction was observed between
baseline and 6 months: 17,25 mm reduction for the transversal diameter, 13,83 mm for
the antero posterior diameter in the TAAA group. Overtime the ratio thrombus volume
/ Total Volume is increasing and the ratio Residual Flow Volume / Total Volume is
decreasing. The problems of thrombosis, shrinkage and volume reduction of the
aneurysmal sac will be discussed. The complications rates with M.F.M appear lower
in comparison with current endovascular techniques, and with surgery.
Conclusions: The M.F.M represents an alternative to current devices to treat TAAA
and AAA. It is a safe procedure with a low complication rate. The ﬁrst results are
promising. A larger study is ongoing.
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Background: Extensive acute deep venous thrombosis (DVT) responds favorably to
catheter directed thrombolysis (CDT). Argatroban is an effective parenteral direct
thrombin inhibitor which makes it an attractive drug for DVT treatment. There is
a paucity of data on the utilization of argatroban in combination with tPA for extensive
DVT.
Methods: 35 patients with extensive DVT involving the femoropopliteal and
iliac veins underwent PEVI. DVT was bilateral in 24 patients. A 6-8 F sheath was
placed in each popliteal vein under ultrasound guidance. DVT had developed within
10 days of major surgery in 7 patients. For maceration of the clot balloon venoplasty
was performed in all. Subsequently an infusion catheter was placed through the
popliteal sheath(s) and tPA delivered at 1mg/hr for 20-24 hours for unilateral DVT
and at 0.75 mg/hr through each infusion catheter for bilateral involvement. For
unilateral DVT, argatroban was given at 0.5 -1 mcg/kg/min through the side port of
the sheath and for bilateral DVT it was given at 0.3- 0.75 mcg/kg/min. PTT was kept
between 50-90 seconds. Every 3 hours the PTT was checked if there was a change in
the Argatroban dose. It was checked every 12 hours if the PTT had remained within
the therapeutic range. Follow-up venography was performed between 20- 30 hours
after PEVI.
Results: With the above regimen there were no bleeding complications even in the 7
patients with recent surgery. Complete or signiﬁcant resolution of thrombus was noted
in 32patients (91%). In 3 patients who previously had occlusive thrombus within their
IVC ﬁlter, the iliac and femoropopliteal DVT had resolved, however some degree of
thrombus in the IVC ﬁlter persisted. These were treated with further thrombectomy
and the procedure terminated at that time with removal of the sheaths.
Conclusions: CDT using a combination of low dose argatroban and tPA is highly
effective and safe in the treatment of massive diffuse DVT. The unacceptably high
rates of bleeding previously reported are not applicable to the contemporary era. A
synergistic effect exists between argatroban and tPA which make them an ideal
anticoagulant- thrombolytic combination for CDT.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-517
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Background: The current recommendation for the treatment of deep venous throm-
bosis (DVT) is at least 5 days of parenteral anticoagulation with a minimum of 24
hours of overlap with a vitamin K antagonist at a therapeutic INR. It has been well
established that percutaneous endovenous intervention(PEVI) reduces the sequelae of
DVT by early removal of thrombus. The efﬁcacy and safety of novel anticoagulants
rivaroxaban and dabigatran following PEVI has not been investigated.
Methods: 93 patients with femoropopliteal , iliac , upper extremity and internal
jugular DVT who had undergone PEVI underwent initiation of dabigatran (34
patients) or rivaroxaban (59 patients) within 2 hours after their procedure. No
parenteral anticoagulation was given when oral anticoagulants were started. The mean
follow up was 183 months. Aspirin at 81mg daily was given to 18 patients who had
received an endovenous stent and was continued for 1 month. The patients were
evaluated for recurrent venous thromboembolic (VTE) disease and bleeding during
the follow- up period.
Results: There was no bleeding or recurrent VTE in any patient. Two patients could
not tolerate dabigatran due to gastrointestinal side effects. The mean duration of
parenteral treatment was 315 hours. Enoxaparin was the parenteral anticoagulant in
32 patients and unfractionated heparin in the remainder. The mean duration of
hospitalization was 295 hours. At follow-up 3 patients died due to cancer.
Conclusions: In patients undergoing PEVI, the duration of safe and effective
parenteral anticoagulation is less than the traditionally accepted minimum of 5 days.
Initiation of rivaroxaban or dabigatran soon after PEVI promotes early discharge and
obviates the inconveniences associated with regulation of INR.
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Background: We present the ﬁrst 55 cases of MFM implanted under indication for
use to treat aortic disease. All were done on compassionate basis, in 11 countries.
Primary Endpoints are Freedom from Rupture and Aneurysm-related Death.
Methods: They were 31 Crawford Thoraco-abdominal (8 Type I, 3 Type II, 9 Type
III, and 11 Type IV), 7 arch, 3 abdominal, 8 suprarenal aortic aneurysms and 6 type B
dissections. Mean age of 64.5 years +/- 18years; mean aneurysm diameter was
6.04cm+/-1.66cm (Median 5.76cm). Mean number of side branches covered was 3.7
per case (median 4, range 0-6). Total 108 stents used, mean of 1.96 MFM per
case.(Median 2, range 1-5)
Results: One-year Aneurysm-related survival was 93.7% (SE+/-4.44%). No rupture
occurred. Technical success was 98.2%. One-year all-cause survival was 84.8%
(SE+/-6.25%). There was no paraplegia. No peri-operative visceral insult. At 12
months all 202 side branches were patent. No stent fractures. One-year intervention-
free survival was 92.4% (SE+/-5.09%) At six months mean rate of sac volume
increase was 0.36% per month. At twelve months the rate of increase had slowed to
0.28% per month. The ratio of thrombus to total volume stayed almost constant over
the 12 months at 0.48, while the ratio of ﬂow to total volume fell from 0.21 to 0.12 at
12 months.
Conclusions: Increasing sac size did not herald rupture. MFM implantation instigates
a process of aortic remodeling involving initial thrombus deposition, which slowed
between six and twelve months .The MFM was not associated with loss of native side
branches.
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Background: To achieve successful revascularization is important for wound healing
in critical limb ischemia (CLI) with tissue loss following endovascular therapy (EVT).
However, we sometimes experience failure to achieve wound healing even after
successful EVT. We investigated the relationship between wound healing and
successful revascularization according to wound types.
Methods: Between April 2007 and April 2012, 171 CLI patients (204 limbs) clas-
siﬁed to Rutherford 5 or 6 were treated by EVT in our institute. In these limbs, 199
individual wounds exited on foot and were evaluated wound healing rates and time to
healing according to their wound types with and without successful revascularization.
Wound types were divided into three groups, group T (Toe wound, n¼128), group Hacts/POSTER/Endovascular Intervention B157







S(Heel wound, n¼28), and group E (Extensive wound extending onto the forefoot or
midfoot along with dorsum or plantar surfaces, n¼43). Successful revascularization
was deﬁned as achievement of direct blood ﬂow to the wounds evaluated by digital
subtraction angiography just after EVT.
Results: We achieved successful revascularization 73% in group T, 79% in group H,
and 51% in group E. In success group, wound healing rates were 81% in group T,
59% in group H, and 32% in group E (p < 0.001). On the other hand, in non-success
group, wound healing rates were 53% in group T, 33% in group H, and 0% in group E
(p < 0.001). Time to healing were 50 days (interquartile range: 23-99 days), and 65
days (28-156 days) in group T (p ¼ 0.20): 145 days (121-317 days), and 260 days
(234-285 days) in group H (p ¼ 0.39) with and without successful revascularization.
Conclusions: Successful revascularization increased wound healing rates of all types
wounds, however, time to healing was not statistically different with and without
successful revascularization. Not only successful revascularization but also various
factors are associated with wound healing in patients with CLI.
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Background: Inferior vena cava ﬁlters (IVCF) have increasingly been used for
prevention of pulmonary thromboembolism (PTE) in deep venous thrombosis (DVP)
when anticoagulant therapy is contraindicated or in patients presumed to be at high
risk. Persistent DVP and risk factors or lack of follow-up may account for IVCF left
permanently in place. We assessed long-term performance of permanent IVCF with
abdominal CT scan.
Methods: ALN IVCF (ALN Implants Chirurgicaux) is a retrievable, non-magnetic,
stainless steel ﬁlter consisting of nine legs. Six short legs (SL) provide anchorage and
three long legs (LL) allow coaxial ﬁlter positioning. Among 54 pts with DVP who
received ALN IVCF, 12 pts (58% female, mean age 55 years, range 19-80) with ﬁlter
left permanently in place underwent abdomen CT scan during follow-up. Six pts had
a second CT scan and one pt had four CT scans. Time from IVCF implantation to CT
scan follow-up ranged from 2 to 163 (mean 60) months. Penetration of ﬁlter into the
IVC wall was deﬁned as  3 mm protrusion of a leg outside the IVC wall. Grade 3
penetration was deﬁned as any interaction with an adjacent organ outside the IVC.
Fracture was deﬁned as any loss in structural integrity of the IVCF. Embolization was
deﬁned as remote endovascular migration of a fractured leg.
Results: In all pts (12/12), CT scan showed penetration of ﬁlter legs. Overall, 57/72
(79%) of the SL but only 1/32 (3%) of the LL were outside IVC wall. Grade 3
penetration of 13 (18%) SL was observed in 8(67%) pts: 9 into a vertebral body and 4
into small intestine. In 4 (33%) pts, 11 (15%) SL fractures were observed, while in 3
(25%) pts embolization of a total of 7 SL occurred: 3 in a pulmonary artery branch, 2
in the right side of the heart, 1 in the liver and 1 whose embolization site was not
found. None of the pts had clinical manifestations related to IVCF dysfunction.
Conclusions: IVC injury and loss of IVCF structural integrity seem to be the rule rather
than the exception after prolonged IVCF positioning. These ﬁndings should encourage
IVCF removal when possible. Furthermore, surveillance follow-up with abdominal
X-ray or CT scan in all patients with permanent IVCF is strongly advisable.
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Background: To compare clinical outcomes of endovascular intervention (EVI)
between octogenarians and non-octogenarians with peripheral arterial disease (PAD)
Methods: A retrospective analysis of 490 consecutive patients (619 legs) who
underwent EVI between June 2005 and February 2013, was conducted in a prospec-
tively maintained database. Patients  80 (128 patients, 158 limbs) and < 80 years old
(362 patients, 461 limbs) were compared to demographics, 30-day major adverse
vascular events (MACE), limb salvage, sustained clinical success (SCS), secondary
sustained clinical success (SSCS) and overall survival.
Results: Patients  80 were more likely to be female and have more atrial ﬁbrillation,
whereas those < 80 were more likely to have diabetes mellitus, dialysis dependence,
hyperlipidemia, high body mass index and claudicants. There were more multi-level
interventions in patients 80 (55%vs. 45%,p¼0.04). Theprocedure success rate (93.7%
vs. 94%, p¼1.0) and 30-day MACE were similar in both age groups (10.1% vs. 9.3%,
p¼1.0). The SCS (<80% vs.80, 56% vs. 53%, p¼0.859), SSCS (<80% vs.80, 72%
vs. 76%, p¼0.07) and limb salvage rates (<80% vs.80, 91% vs. 95%, p¼0.085) wereB158 JACC Vol 62/18/Suppl B j October 27–Nsimilar between both age groups at 24 months. Patients80 still have shorter survival as
compared to those <80 (57% vs. 71%, p<0.01) during the follow-up period.
Conclusions: Our results suggest EVI in octogenarian with more complex lesions is
safe and feasible without increasing the risk of complications. Although the overall
survival remained worse in this elderly group, 24-month SCS, SSCS and limb salvage
rate were similar in both age group. For patients 80 with PAD, EVI should be
considered as ﬁrst-line treatment of choice.
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Background: Although percutaneous transluminal renal artery stenting (PTRAS) has
become popular for treating atherosclerotic renal artery stenosis (ARAS), effect of
statin after PTRAS remains uncertain. The aim of this study is to examine the
inﬂuence of statin after PTRAS.
Methods: Consecutive 268 patients who were diagnosed as atherosclerotic renal
artery stenosis by duplex ultrasound and angiography received renal artery stenting,
and they were enrolled in the study between Aug 1996 and July 2010. Data were
collected on clinical outcomes over a mean follow-up period of 4330 months. The
primary endpoint was deﬁned as the composite of all-cause death, hospitalization of
heart failure, and initiation of dialysis.
Results: 89 patients (33%) received statin treatment during follow-up period.
According to Kaplan-Meier analysis, the log-rank test showed patients who received
statin treatment have a lower event rate than patients without statin (Log-rank test;
p¼0.03), and percentage with event was reduced by 10% in the patients with statin
treatment 5years after PTRAS.Conclusions: In conclusion, statin therapy was associated with a better outcome in
patients with atherosclerotic renal artery stenosis who were received PTRAS.
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Background: There are limited data regarding contemporary use and comparative
clinical outcomes of stent and non-stent based revascularization of infra-inguinal
peripheral arterial vessels.ovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention
